| VSCIX | WEIMX | VSCIX / WEIMX | |
| Total Expense Ratio | 0.03 | 1.28 | 2% |
| Annual Report Gross Expense Ratio | 0.03 | 1.28 | 2% |
| Fund Existence | 29 years | 19 years | - |
| Gain YTD | 14.591 | 25.539 | 57% |
| Front Load | N/A | N/A | - |
| Min. Initial Investment | 5000000 | 500000 | 1,000% |
| Min. Initial Investment IRA | N/A | N/A | - |
| Net Assets | 189B | 203M | 93,103% |
| Annual Yield % from dividends | 1.23 | 0.54 | 229% |
| Returns for 1 year | 22.58 | 9.47 | 238% |
| Returns for 3 years | 43.44 | -20.36 | -213% |
| Returns for 5 years | 35.13 | -41.01 | -86% |
| Returns for 10 years | 156.07 | -22.21 | -703% |
| 1 Day | |||
|---|---|---|---|
| MFs / NAME | Price $ | Chg $ | Chg % |
| GSPKX | 20.05 | 0.12 | +0.60% |
| Goldman Sachs US Eq Div and Prem Instl | |||
| GSIQX | 23.62 | N/A | N/A |
| Goldman Sachs GQG Ptnrs Intl Opps R | |||
| HSIIX | 29.59 | -0.08 | -0.27% |
| Carillon Eagle Small Cap Growth I | |||
| CCWSX | 21.56 | -0.16 | -0.74% |
| Baird Chautauqua International Gr Inv | |||
| RYCFX | 49.56 | -1.15 | -2.27% |
| Rydex Biotechnology C | |||